TESARO

Waltham, MA

TESARO is an oncology-focused biopharmaceutical company focused on acquiring and developing promising drug candidates.  TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has commenced Phase 3 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications.  TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion.